Canine (Canis lupus familiaris) Research Reagents

Антитела и рекомбинантные белки Canine (Canis lupus familiaris) — видоспецифичные валидированные реагенты для исследований. abinScience.

Почему исследователи выбирают abinScience

Видоспецифичная валидация Antibodies validated with confirmed reactivity to your model organism using appropriate positive controls.

Широкий охват мишеней Immune markers, signaling molecules, structural proteins, and disease-relevant biomarkers.

Данные перекрестной реактивности Detailed species cross-reactivity information provided on every product datasheet.

Множество применений Validated for WB, IHC, IF, ELISA, and FC across veterinary, developmental, and comparative biology research.

Оригинальный производитель In-house production with rigorous quality control — reliable supply and consistent quality.

Документы & данные контроля качества

Download product datasheets, валидационные изображения (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

Часто задаваемые вопросы

Как валидируются ваши антитела?

Every antibody is validated in its listed applications (WB, IHC, IF, ELISA, FC) with supporting images and data on the product page. We use positive and negative controls plus knockout/knockdown verification where available.

Предлагаете ли вы конъюгированные антитела?

Yes — HRP, AP, biotin, FITC, PE, APC, Alexa Fluor, and other fluorochrome conjugates are available. Custom conjugation services are also offered for bulk orders.

С какими видами реагируют ваши антитела?

Most antibodies target human, mouse, and rat. Many show validated cross-reactivity with additional species. Check the product datasheet for confirmed reactivity data.

Какова ваша политика замены?

If a product does not perform as described under recommended conditions, contact us within 30 days for replacement or credit. Our technical team will help troubleshoot first.

Могу ли я заказать пользовательские антитела?

Yes — our parent company AtaGenix offers full custom antibody development from immunogen design through hybridoma screening and scale-up production.